RecruitingNot ApplicableNCT06445361
Prevalence of NAFLD in T1DM Patients
The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium
Sponsor
Ziekenhuis Oost-Limburg
Enrollment
138 participants
Start Date
Jul 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
To determine the prevalence of NAFLD in T1DM patients.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study measures how common non-alcoholic fatty liver disease (NAFLD) — a condition where fat builds up in the liver — is among people with type 1 diabetes. Having diabetes increases liver disease risk, but how prevalent it is specifically in type 1 diabetes is not well understood.
**You may be eligible if...**
- You have type 1 diabetes
- You are 18 years of age or older
- You are able to give written informed consent
**You may NOT be eligible if...**
- You drink excessive amounts of alcohol
- You have another identified cause of liver disease or liver fat buildup
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTFibroScan
Performance of a FibroScan measurement to determine steatosis and fibrosis.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06445361
Related Trials
Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)
NCT072937151 location
Prebiotics in Patients With Type 1 Diabetes
NCT049637773 locations
A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500
NCT073413731 location
Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
NCT058428502 locations
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
NCT074575804 locations